Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
None listed
Sponsors
AIIMS
Eligibility
Inclusion criteria
Inclusion criteria: a) Anyone aged >18 years and b) Males; c) Body weight: >50 kg; d) Patients with complete seroconversion; e) Written informed consent to participate in the study. f) Confirmed previous SARS CoV-2 infection with mild symptomatology limited to: 1) cough, 2) fever, 3) myalgia, 4) sore throat, 5) chest pain or pressure, 6) congestion, 7) headache 8) diarrhoea, 9) nausea, and 10) loss of taste or smell.
Exclusion criteria
Exclusion criteria: a) Anyone aged 65 years; b) Females; c) Any comorbid conditions like Diabetes mellitus (uncontrolled), Hypertension (Uncontrolled), Asthma or any other respiratory conditions; d) Patients of COVID-19 with moderate and/ or severe symptomatology; e) Patients with no seroconversion; f) Patients with incomplete seroconversion; g) Failure to obtain Written informed consent; h) Known cases of any malignancy (Cancer COVID-19).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To establish seroconversion in mild symptomatic COVID-19 patients and thence, to establish the safety of the convalescent plasma drawn from such patients for the therapeutic usage in other patients. Timepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| a) To establish the baseline titer of the convalescent plasma drawn from mild symptomatic COVID-19 patients. b) To establish the highest serological dilution which can be effectively used to capture the SARS-CoV-2 antigens. c) To establish the absence of SARS-CoV-2 RNAemia in the drawn convalescent plasma. d) To predict a serological marker to identify potential CVP donors among the recovered patients of mild COID-19.Timepoint: 6 months | — |
Countries
India
Contacts
Public ContactDiptiranjan Rout
AIIMS
Outcome results
None listed